Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Vulvar Neoplasms 1 Vulvar Diseases 1 Uterine Cervical Dysplasia 1 Recurrence 1 Peritoneal Neoplasms 1 Papillomavirus Infections 1 Ovarian Neoplasms 1 Ovarian Diseases 1 Neoplasms, Glandular and Epithelial 1 Neoplasms 1 Immunologic Deficiency Syndromes 1 Glioblastoma 1 Genital Neoplasms, Female 1 Fallopian Tube Neoplasms 1 Epstein-Barr Virus Infections 1 Cytomegalovirus Infections 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma in Situ 1 Adenoviridae Infections 1 Abdominal Neoplasms 1

Interventions

pembrolizumab 90 Blood Specimen Collection 41 Cyclophosphamide 37 Bevacizumab 36 Nivolumab 35 Standard of Care 32 Carboplatin 31 Surveys and Questionnaires 29 Paclitaxel 27 atezolizumab 25 Exercise 25 Pemetrexed 24 Gemcitabine 24 Cisplatin 23 Fluorouracil 22 Radiotherapy 20 Leucovorin 20 Dexamethasone 20 Docetaxel 19 Oxaliplatin 18 Rituximab 16 Irinotecan 16 Cetuximab 16 dostarlimab 15 Drug Therapy 15 Doxorubicin 15 Ipilimumab 14 Biopsy 14 130-nm albumin-bound paclitaxel 14 fludarabine 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Cell Count × 1 year × Clear all

NCT05887882 2026-04-24

PNOC028

University of California, San Francisco

Phase 1 Suspended

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡